J Bone Metab.  2013 Nov;20(2):99-103. 10.11005/jbm.2013.20.2.99.

National Utilization of Calcium Supplements in Patients with Osteoporotic Hip Fracture in Korea

• Kim SH
• Ko YB
• Lee YK
• Hong SW
• Choi HJ
• Ha YC
• Shin CS

• KMID: 2286301
• DOI: http://doi.org/10.11005/jbm.2013.20.2.99

Abstract

BACKGROUND
Calcium is prescribed worldwide for patients diagnosed with osteoporosis. However, the national utilization of calcium and compliance with calcium is unclear in Korea. Our purpose is to evaluate Korea's national utilization of calcium and compliance with calcium in patients with osteoporotic hip fracture from 2007 to 2010 using data from the Health Insurance Review and Assessment (HIRA) Service.
METHODS
From 2007 to 2011, osteoporotic hip fractures were identified using the International Classification of Diseases, 10th revision (ICD-10) and procedure code form from the nationwide database of the Health Insurance Review and Assessment Service. Compliant users of calcium were defined as the patients' medication possession ratio of 80 or more. We analyzed the compliance of calcium according to age and gender.
RESULTS
Among 85,228 patients with hip fracture, 20,800 patients (24.4%) received a prescription of a calcium supplement. Among them, only 1,692 patients (8.1%) were identified as compliant users of calcium. The proportion of compliant users was higher in women than men in all age groups. The proportion of compliant users decreased with age in women.
CONCLUSIONS
In Korea, the national utilization of calcium was low and compliance with calcium was unsatisfactory even in patients with osteoporotic hip fracture.

Keyword

Calcium; Compliance; Hip fractures; Osteoporosis; Osteoporotic fractures

MeSH Terms

Calcium*
Compliance
Female
Hip Fractures
Hip*
Humans
Insurance, Health
International Classification of Diseases
Korea*
Male
Osteoporosis
Osteoporotic Fractures
Prescriptions
Calcium

Figure

• 

  Fig. 1 Proportion of patients with calcium prescription after hip fracture from 2007 to 2010.

• 

  Fig. 2 Proportion of compliant user (medication possession ratio [MPR] ≥ 80) of calcium according to age.

Reference

1. Park C, Ha YC, Jang S, et al. The incidence and residual lifetime risk of osteoporosis-related fractures in Korea. J Bone Miner Metab. 2011; 29:744–751.

2. Cummings SR, Melton LJ. Epidemiology and outcomes of osteoporotic fractures. Lancet. 2002; 359:1761–1767.

3. Haentjens P, Autier P, Collins J, et al. Colles fracture, spine fracture, and subsequent risk of hip fracture in men and women. A meta-analysis. J Bone Joint Surg Am. 2003; 85:1936–1943.

4. Salaffi F, Cimmino MA, Malavolta N, et al. The burden of prevalent fractures on health-related quality of life in postmenopausal women with osteoporosis: the IMOF study. J Rheumatol. 2007; 34:1551–1560.

5. Yoon HK, Park C, Jang S, et al. Incidence and mortality following hip fracture in Korea. J Korean Med Sci. 2011; 26:1087–1092.

6. Lee YK, Ha YC, Yoon BH, et al. Incidence of second hip fracture and compliant use of bisphosphonate. Osteoporos Int. 2013; 24:2099–2104.

7. Lee YK, Ha YC, Choi HJ, et al. Bisphosphonate use and subsequent hip fracture in South Korea. Osteoporos Int. 2013; doi: 10.1007/s00198-013-2395-5.

8. National Osteoporosis Foundation. Physician's guide to prevention and treatment of osteoporosis. 2003. cited by 2006 Feb 15. Available from: http://www.nof.org/phys-guide/.

9. Javid KS, Thien A, Hill R. Implementation of and compliance with NICE guidelines in the secondary prevention of osteoporotic fractures in postmenopausal women. Ann R Coll Surg Engl. 2008; 90:213–215.

10. American Association of Clinical Endocrinologists. AACE clinical practice guidelines for the prevention and treatment of postmenopausal osteoporosis. J Fla Med Assoc. 1996; 83:552–566.

11. Jang S, Park C, Jang S, et al. Medical service utilization with osteoporosis. Endocrinol Metab. 2010; 25:326–339.

12. Lee YK, Kim S, Kim KC, et al. Domestic characteristics and trends of publications on bone metabolism in South Korea between 1998 and 2012. J Bone Metab. 2013; 20:43–45.

13. Russell RG, Watts NB, Ebetino FH, et al. Mechanisms of action of bisphosphonates: similarities and differences and their potential influence on clinical efficacy. Osteoporos Int. 2008; 19:733–759.

14. Bilezikian JP. Efficacy of bisphosphonates in reducing fracture risk in postmenopausal osteoporosis. Am J Med. 2009; 122:S14–S21.

15. Watts NB. Risedronate for the prevention and treatment of postmenopausal osteoporosis: results from recent clinical trials. Osteoporos Int. 2001; 12:Suppl 3. S17–S22.

16. Boonen S, Vanderschueren D, Haentjens P, et al. Calcium and vitamin D in the prevention and treatment of osteoporosis - a clinical update. J Intern Med. 2006; 259:539–552.

17. Ensrud KE, Black DM, Palermo L, et al. Treatment with alendronate prevents fractures in women at highest risk: results from the Fracture Intervention Trial. Arch Intern Med. 1997; 157:2617–2624.

18. Harris ST, Watts NB, Genant HK, et al. Vertebral Efficacy With Risedronate Therapy (VERT) Study Group. Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. JAMA. 1999; 282:1344–1352.

19. Nowson CA. Prevention of fractures in older people with calcium and vitamin D. Nutrients. 2010; 2:975–984.

20. Chapuy MC, Meunier PJ. Prevention of secondary hyperparathyroidism and hip fracture in elderly women with calcium and vitamin D3 supplements. Osteoporos Int. 1996; 6:Suppl 3. 60–63.

21. Lee YK, Nho JH, Ha YC, et al. Persistence with intravenous zoledronate in elderly patients with osteoporosis. Osteoporos Int. 2012; 23:2329–2333.

22. Choi HJ, Shin CS, Ha YC, et al. Burden of osteoporosis in adults in Korea: a national health insurance database study. J Bone Miner Metab. 2012; 30:54–58.

23. Lee YK, Ha YC, Park C, et al. Bisphosphonate use and increased incidence of subtrochanteric fracture in South Korea: results from the National Claim Registry. Osteoporos Int. 2013; 24:707–711.

24. Lee YK, Jang S, Jang S, et al. Mortality after vertebral fracture in Korea: analysis of the National Claim Registry. Osteoporos Int. 2012; 23:1859–1865.

25. Gold DT, Martin BC, Frytak JR, et al. A claims database analysis of persistence with alendronate therapy and fracture risk in post-menopausal women with osteoporosis. Curr Med Res Opin. 2007; 23:585–594.

26. Siris ES, Harris ST, Rosen CJ, et al. Adherence to bisphosphonate therapy and fracture rates in osteoporotic women: relationship to vertebral and nonvertebral fractures from 2 US claims databases. Mayo Clin Proc. 2006; 81:1013–1022.

27. Soong YK, Tsai KS, Huang HY, et al. Risk of refracture associated with compliance and persistence with bisphosphonate therapy in Taiwan. Osteoporos Int. 2013; 24:511–521.

28. Stafford RS, Drieling RL, Johns R, et al. National patterns of calcium use in osteoporosis in the United States. J Reprod Med. 2005; 50:885–890.

29. Norman M, Parker MJ. Compliance with a pharmacological secondary fracture prevention policy. Injury. 2006; 37:718–720.

30. Baek JH, Lee YK, Hong SW, et al. Knowledge on osteoporosis in guardians of hip fracture patients. J Bone Miner Metab. 2013; 31:481–484.

31. Wilson RK, Tomlinson G, Stas V, et al. Male and non-English-speaking patients with fracture have poorer knowledge of osteoporosis. J Bone Joint Surg Am. 2011; 93:766–774.

32. Nguyen NV, Dinh TA, Ngo QV, et al. Awareness and knowledge of osteoporosis in Vietnamese women. Asia Pac J Public Health. 2011; doi: 10.1177/1010539511423569.

33. Whiting SJ, Wood RJ. Adverse effects of high-calcium diets in humans. Nutr Rev. 1997; 55:1–9.

34. Albertazzi P, Steel SA, Howarth EM, et al. Comparison of the effects of two different types of calcium supplementation on markers of bone metabolism in a postmenopausal osteopenic population with low calcium intake: a double-blind placebo-controlled trial. Climacteric. 2004; 7:33–40.